Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation

Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation

Bibliographic Details
Main Authors: Benjamin A. Derman, Andrew T. Stefka, Ken Jiang, Amanda McIver, Tadeusz Kubicki, Jagoda K. Jasielec, Andrzej J. Jakubowiak
Format: Article
Language:English
Published: Nature Publishing Group 2021-02-01
Series:Blood Cancer Journal
Online Access:https://doi.org/10.1038/s41408-021-00418-2

Internet

https://doi.org/10.1038/s41408-021-00418-2

Similar Items